Narsoplimab Injection
- Medicine Name: Narsoplimab
- API: Narsoplimab
- Dosage Form & Strength: Single-dose vials
- Manufactured By: Omeros
Narsoplimab, also known as OMS721, is a monoclonal antibody that targets and inhibits the activation of the lectin pathway of the complement system. It is being investigated for its potential medical uses in various conditions, including Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA), IgA Nephropathy, and Atypical Hemolytic Uremic Syndrome (aHUS).
Recommended Dosage: The recommended dosage of Narsoplimab injection is typically based on body weight and administered intravenously. The dosing regimen may be adjusted by the healthcare provider based on the patient’s response to treatment and any adverse effects experienced.
- Narsoplimab can cause hypersensitivity reactions, including anaphylaxis. Patients should be monitored closely for signs of allergic reactions during treatment, and appropriate medical interventions should be available.
- Narsoplimab may increase the risk of infections, including serious or life-threatening infections. Patients should be monitored for signs of infection during treatment, and appropriate measures should be taken to manage infections promptly.
- Narsoplimab may increase the risk of thrombosis (blood clots) or thromboembolic events. Patients with a history of thrombotic events or those at increased risk for thrombosis should be closely monitored during treatment.
- Liver function tests should be conducted regularly during treatment with Narsoplimab. Patients with pre-existing liver conditions may require closer monitoring, and dose adjustments may be necessary based on liver function test results.
- The safety of Narsoplimab during pregnancy and breastfeeding has not been established. Pregnant or breastfeeding individuals should consult with their healthcare provider before initiating treatment with Narsoplimab to weigh the potential risks and benefits.
What documents are required to import NARSOPLIMAB to India?
NARSOPLIMAB injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
How does the order be confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from the Doctor
- Import permit if applicable
Is NARSOPLIMAB available in India?
NARSOPLIMAB injection is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Narsoplimab in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
IPN (Indian Pharma Network) can facilitate the supply of NARSOPLIMAB (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Narsoplimab injection price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
What is Narsoplimab?
Narsoplimab is a novel therapeutic agent designed to target and inhibit the activity of mannan-binding lectin-associated serine protease-2 (MASP-2), a key component of the lectin pathway of the complement system. It is being investigated for its potential in treating various complement-mediated disorders.
What conditions is Narsoplimab being studied for?
Narsoplimab is currently being studied for its efficacy and safety in treating several complement-mediated disorders, including hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), immunoglobulin A nephropathy (IgAN), and atypical hemolytic uremic syndrome (aHUS).
How does Narsoplimab work?
Narsoplimab works by selectively inhibiting MASP-2, a protein involved in the activation of the complement system. By targeting this specific pathway, Narsoplimab aims to reduce excessive complement activation, which can lead to tissue damage and inflammation in various diseases.
What are the potential benefits of Narsoplimab?
The potential benefits of Narsoplimab include the ability to mitigate complement-mediated tissue damage and inflammation, thereby improving outcomes for patients with conditions such as HSCT-TMA, IgAN, and aHUS. Clinical trials are ongoing to assess its efficacy, safety, and tolerability.
Is Narsoplimab approved for use?
Narsoplimab has not yet received regulatory approval for any indication. It is currently being evaluated in clinical trials to determine its effectiveness and safety profile. Regulatory approval would be required before Narsoplimab can be made available for widespread use in treating complement-mediated disorders.
How much does Narsoplimab cost in India?
The cost of Narsoplimab in India can vary. To procure this therapeutic drug legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Narsoplimab?
Store Narsoplimab at room temperature between 68°F to 77°F (20°C to 25°C). Avoid exposing it to extreme heat or cold temperatures. Keep Narsoplimab vials protected from light in their original packaging.
Is it safe to buy Narsoplimab online in India?
Yes, one can buy Narsoplimab online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can facilitate the supply of Narsoplimab injections through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.